{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:06:09Z","timestamp":1773155169512,"version":"3.50.1"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b16-00440","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T22:08:39Z","timestamp":1477951719000},"page":"1852-1858","source":"Crossref","is-referenced-by-count":13,"title":["An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects"],"prefix":"10.1248","volume":"39","author":[{"given":"Naoki","family":"Mukoyama","sequence":"first","affiliation":[{"name":"Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshimi","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University"},{"name":"Department of Psychiatry, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Kotani","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University"},{"name":"Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyofumi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Kikkawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Genecology, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Noda","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University"},{"name":"Department of Psychiatry, Graduate School of Medicine, Nagoya University"},{"name":"Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit. Rev. Oncol. Hematol.<\/i>, 99<\/b>, 13\u201336 (2016).","DOI":"10.1016\/j.critrevonc.2015.12.001"},{"key":"2","unstructured":"2) Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J. Support. Oncol.<\/i>, 5<\/b> (Suppl. 3), 1\u20139 (2007)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol.<\/i>, 24<\/b>, 2932\u20132947 (2006).","DOI":"10.1200\/JCO.2006.06.9591"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hesketh PJ. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med.<\/i>, 358<\/b>, 2482\u20132494 (2008).","DOI":"10.1056\/NEJMra0706547"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol.<\/i>, 19<\/b>, 1759\u20131767 (2001).","DOI":"10.1200\/JCO.2001.19.6.1759"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol.<\/i>, 21<\/b>, 2147\u20132155 (2003).","DOI":"10.1200\/JCO.2003.05.164"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kaiser R, Tremblay PB, Sezer O, Possinger K, Roots I, Brockm\u00f6ller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics<\/i>, 14<\/b>, 271\u2013278 (2004).","DOI":"10.1097\/00008571-200405000-00001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Fasching PA, Kollmannsberger B, Strissel PL, Niesler B, Engel J, Kreis H, Lux MP, Weihbrecht S, Lausen B, Bani MR, Beckmann MW, Strick R. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J. Cancer Res. Clin. Oncol.<\/i>, 134<\/b>, 1079\u20131086 (2008).","DOI":"10.1007\/s00432-008-0387-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, Di Giorgio A, Taurisano P, Papp A, Pinsonneault J, Wang D, Nardini M, Popolizio T, Sadee W. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain<\/i>, 132<\/b>, 417\u2013425 (2008).","DOI":"10.1093\/brain\/awn248"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bertolino A, Fazio L, Di Giorgio A, Blasi G, Romano R, Taurisano P, Caforio G, Sinibaldi L, Ursini G, Popolizio T, Tirotta E, Papp A, Dallapiccola B, Borrelli E, Sadee W. Genetically determined interaction between the dopamine transporter and the D2<\/sub> receptor on prefronto-striatal activity and volume in humans. J. Neurosci.<\/i>, 29<\/b>, 1224\u20131234 (2009).","DOI":"10.1523\/JNEUROSCI.4858-08.2009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hos\u00e1k L. Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur. Psychiatry<\/i>, 22<\/b>, 276\u2013281 (2007).","DOI":"10.1016\/j.eurpsy.2007.02.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee ML, Xiao T, Papp A, Wang D, Sad\u00e9e W. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 104<\/b>, 20552\u201320557 (2007).","DOI":"10.1073\/pnas.0707106104"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Poon M, Hwang J, Dennis K, DeAngelis C, Zhang L, Chung H, Stinson J, Wong S, Pulenzas N, Chow E. A novel prospective descriptive analysis of nausea and vomiting among patients receiving gastrointestinal radiation therapy. Support. Care Cancer<\/i>, 24<\/b>, 1545\u20131561 (2016).","DOI":"10.1007\/s00520-015-2942-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J. Natl. Cancer Inst.<\/i>, 104<\/b>, 1280\u20131292 (2012).","DOI":"10.1093\/jnci\/djs335"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Bayo J, Fonseca PJ, Hernando S, Servitja S, Calvo A, Falagan S, Garc\u00eda E, Gonz\u00e1lez I, de Miguel MJ, P\u00e9rez Q, Milena A, Ruiz A, Barnadas A. Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles. Clin. Transl. Oncol.<\/i>, 14<\/b>, 413\u2013422 (2012).","DOI":"10.1007\/s12094-012-0818-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann. Oncol.<\/i>, 27<\/b>, 172\u2013178 (2016).","DOI":"10.1093\/annonc\/mdv482"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll HJ, Landenberger M. Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Support. Care Cancer<\/i>, 17<\/b>, 1543\u20131552 (2009).","DOI":"10.1007\/s00520-009-0698-z"},{"key":"18","unstructured":"18) National Cancer Institute. \u201cCommon Terminology Criteria for Adverse Events (CTCAE) v4.0\u201d: \u2039http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html\u203a, cited 5 August, 2016."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int. J. Clin. Oncol.<\/i>, 20<\/b>, 855\u2013865 (2015).","DOI":"10.1007\/s10147-015-0786-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J. Pain Symptom Manage.<\/i>, 47<\/b>, 839\u2013848.e4 (2014).","DOI":"10.1016\/j.jpainsymman.2013.06.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Rha SY, Park Y, Song SK, Lee CE, Lee J. Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. Support. Care Cancer<\/i>, 24<\/b>, 3379\u20133389 (2016).","DOI":"10.1007\/s00520-016-3146-x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Vanbockstael J, Coquan E, Gouerant S, Allouache D, Faveyrial A, Noal S, Delcambre C, Galais MP, H\u00e9ron JF, Lefebvre AC, Sevin E, Hrab I, Polycarpe F, Andr\u00e9 M, Kaluzinski L, Gervais R, Gunzer K, Vi\u00e9 B, Saucier G, Lemenand N, Grellard JM, Clarisse B, Dugu\u00e9 AE, Joly F. How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study. Support. Care Cancer<\/i>, 24<\/b>, 1131\u20131138 (2016).","DOI":"10.1007\/s00520-015-2882-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P. Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support. Care Cancer<\/i>, 19<\/b>, 1549\u20131563 (2011).","DOI":"10.1007\/s00520-010-0982-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Molassiotis A, Stamataki Z, Kontopantelis E. Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support. Care Cancer<\/i>, 21<\/b>, 2759\u20132767 (2013).","DOI":"10.1007\/s00520-013-1843-2"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Roscoe JA, Hickok JT, Morrow GR. Patient expectations as predictor of chemotherapy-induced nausea. Ann. Behav. Med.<\/i>, 22<\/b>, 121\u2013126 (2000).","DOI":"10.1007\/BF02895775"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, Banerjee TK. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer<\/i>, 101<\/b>, 2701\u20132708 (2004).","DOI":"10.1002\/cncr.20718"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group. Support. Care Cancer<\/i>, 5<\/b>, 307\u2013313 (1997).","DOI":"10.1007\/s005200050078"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support. Care Cancer<\/i>, 20<\/b>, 107\u2013117 (2012).","DOI":"10.1007\/s00520-010-1073-9"},{"key":"29","unstructured":"29) Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J. Support. Oncol.<\/i>, 5<\/b>, 374\u2013380 (2007)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Fraunholz I, Grau K, Wei\u00df C, R\u00f6del C. Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther. Onkol.<\/i>, 187<\/b>, 1\u20136 (2011).","DOI":"10.1007\/s00066-010-2196-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support. Care Cancer<\/i>, 18<\/b>, 1171\u20131177 (2010).","DOI":"10.1007\/s00520-009-0737-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci.<\/i>, 104<\/b>, 711\u2013717 (2013).","DOI":"10.1111\/cas.12146"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockm\u00f6ller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol.<\/i>, 20<\/b>, 2805\u20132811 (2002).","DOI":"10.1200\/JCO.2002.09.064"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin. Pharmacol. Ther.<\/i>, 78<\/b>, 619\u2013626 (2005).","DOI":"10.1016\/j.clpt.2005.08.015"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM. Race influences warfarin dose changes associated with genetic factors. Blood<\/i>, 126<\/b>, 539\u2013545 (2015).","DOI":"10.1182\/blood-2015-02-627042"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/11\/39_b16-00440\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:28:42Z","timestamp":1498357722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/11\/39_b16-00440\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00440","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}